Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Cancer

PUBLISHER: Grand View Research | PRODUCT CODE: 1511982

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1511982

Skin Cancer Diagnostics Market Size, Share & Trends Analysis Report By Cancer Type (Melanoma, Non-Melanoma), By Test Type (Dermatoscopy, Skin Biopsy, Lymph Node Biopsy), By End-use, By Region, And Segment Forecasts, 2024 - 2030

PUBLISHED:
PAGES: 125 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 5950
Printable PDF (5-User License)
USD 6950
Printable PDF (Enterprise License)
USD 8950

Add to Cart

Description

Table of Contents

List of Tables

Skin Cancer Diagnostics Market Growth & Trends:

The global skin cancer diagnostics market size is anticipated to reach USD 13.23 billion by 2030 and is expected to expand at a CAGR of 5.52% from 2024 to 2030, according to a new report by Grand View Research, Inc. The skin cancer diagnostics market is driven by several key factors. Rising skin cancer incidence due to increased UV exposure and aging populations is a primary driver. Advances in diagnostic technologies, such as AI-powered imaging and molecular diagnostics, enhance accuracy and early detection, further propelling market growth. Increased awareness campaigns and government initiatives promoting early screening also contribute significantly. In addition, higher healthcare expenditures and improved access to dermatological care are crucial in expanding the skin cancer diagnostics market.

Over the past decade, significant advancements have been made in approaches to melanoma detection, all aimed at reducing the growing incidence of melanoma and its mortality rate. While these advancements have been well-documented to increase early melanoma detection, there has been considerable criticism of their efficacy in improving survival rates. Traditional methods for detecting skin cancer often involve time-consuming and expensive procedures, such as PET and CT scans, as well as invasive technologies using higher frequencies.

A biosensor developed at Queen Mary University of London in April 2024 offers a noninvasive and highly efficient solution. This biosensor leverages the unique properties of THz waves, which have lower energy than X-rays and are safe for humans, to detect subtle changes in cell characteristics. In addition, scientists have developed genomic tests that provide oncologists and dermatologists with valuable information about the molecular biology of tumors, particularly in patients with aggressive skin cancers such as invasive melanomas and high-risk Squamous Cell Carcinomas (SCCs). These tests analyze genetic information from a patient's primary tumor, helping physicians better forecast the likelihood of cancer recurrence after treatment and its potential spread to other parts of the body. Furthermore, these tests offer greater patient-specific insights that are not available through traditional cancer staging, which typically uses clinical information and lab reports compared with population-based data to determine a patient's prognosis.

In the era of COVID-19, teledermatology has become increasingly popular. These emerging techniques for skin cancer diagnosis have the potential to be integrated into teledermatology in primary care settings. Furthermore, combining AI with these emerging techniques can further enhance their widespread use. More large-scale, multicenter, prospective clinical trials are needed to prevent these emerging techniques from remaining experimental equipment used in only a few special centers. This can be achieved by maintaining interest in this issue among health providers, the general population, patients, and health-related organizations in each country.

Skin Cancer Diagnostics Market Report Highlights:

  • Nonmelanoma dominated the cancer type segment and is anticipated to grow at fastest growth rate over the forecast period owing to the owing to the rising incidence of Nonmelanoma Skin Cancer (NMSC) and development of novel diagnostics tools for the diagnosis of no melanoma cancer
  • Skin biopsy dominated the test type segment. Skin biopsies are pivotal in skin cancer diagnostics, serving as the gold standard for definitive diagnosis. Market driving factors include the rising prevalence, advancements in biopsy techniques, and improved pathological analysis. Increased awareness and screening programs promote early detection, boosting biopsy demand
  • Imaging segment is expected to grow at faster rate during the review period. Factors such as the rising incidence of skin cancer, technological advancements in imaging modalities (like dermoscopy, optical coherence tomography, and reflectance confocal microscopy), and increasing awareness about early detection contribute to market expansion. Additionally, the growing adoption of non-invasive imaging techniques, which offer improved accuracy and reduced patient discomfort, further propel market growth
  • Hospitals and clinics segment dominated the end-use segment and is anticipated to grow at fastest growth rate over the forecast period. As diagnostics are being increasingly adopted, their acceptance has increased in hospitals as well. Developments in hospital laboratories are crucial to address the evolving needs of patients, and more hospitals are aiming to provide a wide range of services in their settings
  • North America dominated the skin cancer diagnostics market owing to factors such as the presence of major key players, favorable government initiatives for the development of innovative diagnostics tools
Show more
Product Code: GVR-4-68040-322-6

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Cancer Type
    • 1.2.2. Test Type
    • 1.2.3. End-use
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research End-use
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Cancer Type and test type outlook
    • 2.2.2. End-use outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Skin Cancer Diagnostics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Technological advancements
      • 3.2.1.2. Integration of artificial intelligence
      • 3.2.1.3. Patient preference for non-invasive diagnostics
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High Cost of Diagnostic Imaging
  • 3.3. Skin Cancer Diagnostics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Skin Cancer Diagnostics Market: Cancer Type Estimates & Trend Analysis

  • 4.1. Global Skin Cancer Diagnostics Market: Cancer Type Dashboard
  • 4.2. Global Skin Cancer Diagnostics Market: Cancer Type Movement Analysis
  • 4.3. Global Skin Cancer Diagnostics Market by Cancer Type, Revenue
  • 4.4. Melanoma
    • 4.4.1. Melanoma market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Non-Melanoma
    • 4.5.1. Non-Melanoma market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Skin Cancer Diagnostics Market: Test Type Estimates & Trend Analysis

  • 5.1. Global Skin Cancer Diagnostics Market: Test Type Dashboard
  • 5.2. Global Skin Cancer Diagnostics Market: Test Type Movement Analysis
  • 5.3. Global Skin Cancer Diagnostics Market by Test Type, Revenue
  • 5.4. Dermatoscopy
    • 5.4.1. Dermatoscopy market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Skin Biopsy
    • 5.5.1. Skin Biopsy market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Lymph node biopsy
    • 5.6.1. Lymph node biopsy market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. Imaging Tests
    • 5.7.1. Imaging Tests market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8. Others
    • 5.8.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Skin Cancer Diagnostics Market: Test Type Estimates & Trend Analysis

  • 6.1. Global Skin Cancer Diagnostics Market: End-use Dashboard
  • 6.2. Global Skin Cancer Diagnostics Market: End-use Movement Analysis
  • 6.3. Global Skin Cancer Diagnostics Market by End-use, Revenue
  • 6.4. Hospital and Clinics
    • 6.4.1. Hospital and Clinics market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Laboratories
    • 6.5.1. Laboratories market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Others Analysis market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Skin Cancer Diagnostics Market: Regional Estimates & Trend Analysis by Cancer Type, Test Type and End-use

  • 7.1. Regional Dashboard
  • 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.3. North America
    • 7.3.1. U.S.
      • 7.3.1.1. Key country dynamics
      • 7.3.1.2. Regulatory framework/ reimbursement structure
      • 7.3.1.3. Competitive scenario
      • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.2. Canada
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Regulatory framework/ reimbursement structure
      • 7.3.2.3. Competitive scenario
      • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. France
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework/ reimbursement structure
      • 7.4.4.3. Competitive scenario
      • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Regulatory framework/ reimbursement structure
      • 7.4.5.3. Competitive scenario
      • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.6. Norway
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Regulatory framework/ reimbursement structure
      • 7.4.6.3. Competitive scenario
      • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Regulatory framework/ reimbursement structure
      • 7.4.7.3. Competitive scenario
      • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Regulatory framework/ reimbursement structure
      • 7.4.8.3. Competitive scenario
      • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. China
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. India
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. South Korea
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework/ reimbursement structure
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Mexico
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.3. Argentina
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework/ reimbursement structure
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2023
    • 8.3.4. Castle Bioscience
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. DermTech
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. bioMerieux , Inc.
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. FOUNDATION MEDICINE, INC.
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. DermaSensor, Inc.
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. F . Hoffmann-La Roche Ltd
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. NeoGenomics Laboratories
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Quest Diagnostics Incorporated
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. SkylineDx
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Product benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. Abbott
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Product benchmarking
      • 8.3.13.4. Strategic initiatives
Show more
Product Code: GVR-4-68040-322-6

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America skin cancer diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 4 North America skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 5 North America skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 6 U.S. skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 7 U.S. skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 8 U.S. skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 9 Canada skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 10 Canada skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 11 Canada skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 12 Europe skin cancer diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 13 Europe skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 14 Europe skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 15 Europe skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 16 Germany skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 17 Germany skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 18 Germany skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 19 UK skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 20 UK skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 21 UK skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 22 France skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 23 France skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 24 France skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 25 Italy skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 26 Italy skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 27 Italy skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 28 Spain skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 29 Spain skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 30 Spain skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 31 Denmark skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 32 Denmark skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 33 Denmark skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 34 Sweden skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 35 Sweden skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 36 Sweden skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 37 Norway skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 38 Norway skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 39 Norway skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 40 Asia Pacific skin cancer diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 44 China skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 45 China skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 46 China skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 47 Japan skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 48 Japan skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 49 Japan skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 50 India skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 51 India skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 52 India skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 53 South Korea skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 54 South Korea skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 55 South Korea skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 56 Australia skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 57 Australia skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 58 Australia skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 59 Thailand skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 60 Thailand skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 61 Thailand skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 62 Latin America skin cancer diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 63 Latin America skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 64 Latin America skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 65 Latin America skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 66 Brazil skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 67 Brazil skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 68 Brazil skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 69 Mexico skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 70 Mexico skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 71 Mexico skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 72 Argentina skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 73 Argentina skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 74 Argentina skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 75 MEA skin cancer diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 76 MEA skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 77 MEA skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 78 MEA skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 79 South Africa skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 80 South Africa skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 81 South Africa skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 84 Saudi Arabia skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 85 UAE skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 86 UAE skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 87 UAE skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 88 Kuwait skin cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
  • Table 89 Kuwait skin cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 90 Kuwait skin cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Skin cancer diagnostics market: market outlook
  • Fig. 14 Skin cancer diagnostics competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Skin cancer diagnostics market driver impact
  • Fig. 18 Skin cancer diagnostics market restraint impact
  • Fig. 19 Skin cancer diagnostics market: Cancer Type movement analysis
  • Fig. 20 Skin cancer diagnostics market: Cancer Type outlook and key takeaways
  • Fig. 21 Melanoma market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Non-Melanoma estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Skin cancer diagnostics market: Test Type movement analysis
  • Fig. 24 Skin cancer diagnostics market: Test Type outlook and key takeaways
  • Fig. 25 Dermatoscopy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Skin biopsy estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Lymph node biopsy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Imaging tests market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Others estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Skin cancer diagnostics market: End-use movement analysis
  • Fig. 31 Skin cancer diagnostics market: End-use outlook and key takeaways
  • Fig. 32 Hospital and clinics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Laboratories estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 34 Others estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Global skin cancer diagnostics market: Regional movement analysis
  • Fig. 36 Global skin cancer diagnostics market: Regional outlook and key takeaways
  • Fig. 37 Global skin cancer diagnostics market share and leading players
  • Fig. 38 North America, by country
  • Fig. 39 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 U.S. key country dynamics
  • Fig. 41 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Canada key country dynamics
  • Fig. 43 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 UK key country dynamics
  • Fig. 46 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Germany key country dynamics
  • Fig. 48 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 France key country dynamics
  • Fig. 50 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Italy key country dynamics
  • Fig. 52 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Spain key country dynamics
  • Fig. 54 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Denmark key country dynamics
  • Fig. 56 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Sweden key country dynamics
  • Fig. 58 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Norway key country dynamics
  • Fig. 60 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 China key country dynamics
  • Fig. 63 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Japan key country dynamics
  • Fig. 65 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 India key country dynamics
  • Fig. 67 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Thailand key country dynamics
  • Fig. 69 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 South Korea key country dynamics
  • Fig. 71 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 Australia key country dynamics
  • Fig. 73 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 75 Brazil key country dynamics
  • Fig. 76 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 77 Mexico key country dynamics
  • Fig. 78 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 Argentina key country dynamics
  • Fig. 80 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 82 South Africa key country dynamics
  • Fig. 83 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 84 Saudi Arabia key country dynamics
  • Fig. 85 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 UAE key country dynamics
  • Fig. 87 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 88 Kuwait key country dynamics
  • Fig. 89 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 90 Market share of key market players - Skin cancer diagnostics market
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!